Cancer Drug Growth Stabilizes Pfizer's Q3 Results

Pfizer's oncology segment does its best to make up for ongoing patent expirations in previously key drugs.

Topics:  drug   pfizer's   
BING NEWS:
  • Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
    Pfizer announced positive results from a pivotal clinical trial evaluating Abrysvo's efficacy against respiratory syncytial virus. See why PFE stock is a Buy.
    04/19/2024 - 12:03 am | View Link
  • Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
    Nonetheless, Pfizer expects better non-COVID operational revenue growth in the future quarters ... of Seagen added a class of antibody-drug conjugates or ADCs, Adcetris, Padcev, Tukysa and Tivdak, to ...
    04/11/2024 - 2:12 am | View Link
  • Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access
    Pfizer (PFE) said key data from an ongoing phase 3 clinical trial of its Abrysvo vaccine, which the pharmaceutical giant is developing for the treatment of respiratory syncytial virus, or RSV, met ...
    04/9/2024 - 1:49 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News